FDA warns of heart-related events, cancer, blood clots, and death for JAK inhibitors
The FDA on Wednesday wrapped up its long-awaited review of Pfizer’s large, randomized trial evaluating the safety of its JAK inhibitors Xeljanz and Xeljanz XR …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
